Clinical Trial: A Single-Center, Randomized, Controlled, Open-Label Phase II Clinical Study Comparing the Efficacy and Safety of rhTPO Versus Trilaciclib for Secondary Prophylaxis of Chemotherapy-Induced Thrombocytopenia (CTIT) in Solid Tumors (China)

China, Sept. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Center, Randomized, Controlled, Open-Label Phase II Clinical Study Comparing the Efficacy and Safety of rhTPO Versus Trilaciclib for Secondary Prophylaxis of Chemotherapy-Induced Thrombocytopenia (CTIT) in Solid Tumors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132980

Registration Time: 2026/09/20

Type: Interventional study

Primary Sponsor: Affiliated hangzhou first people's hospital, zhejiang university school of medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335017

Published by HT Digital Content Services with permission fro...